{
    "clinical_study": {
        "@rank": "105857", 
        "arm_group": [
            {
                "arm_group_label": "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination"
            }, 
            {
                "arm_group_label": "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination"
            }, 
            {
                "arm_group_label": "PPI-668, BI 207127 Dose 1, and Faldaprevir", 
                "arm_group_type": "Active Comparator", 
                "description": "PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to provide a preliminary assessment of the safety and effectiveness\n      of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the\n      treatment of chronic hepatitis C virus infection."
        }, 
        "brief_title": "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 18 to 65 years of age; if females are of childbearing potential, then\n             they must be willing to use two non-hormonal methods of birth control\n\n          2. Body weight greater than 40 kg and less than 125 kg\n\n          3. Clinical diagnosis of chronic hepatitis C\n\n          4. Treatment-na\u00efve for hepatitis C:  no previous treatment with interferon, pegylated\n             interferon, ribavirin, telaprevir, boceprevir, or any investigational therapies for\n             hepatitis C\n\n          5. No symptoms or signs of intercurrent illness at Screen (other than those attributable\n             to hepatitis C)\n\n          6. No clinically significant abnormalities in the 12-lead electrocardiogram at Screen\n\n          7. Signed informed consent prior to trial participation.\n\n        Exclusion Criteria:\n\n          1. Seropositive for HIV antibody or Hepatitis B Surface Antigen at Screen\n\n          2. Liver disease due to causes other than chronic HCV infection\n\n          3. Symptoms or signs of decompensated liver disease, or evidence of cirrhosis\n\n          4. Any medical condition that may interfere with the absorption, distribution or\n             elimination of study drugs\n\n          5. Poorly controlled or unstable hypertension at Screen.\n\n          6. Clinically significant, unstable cardiovascular or pulmonary disease, including\n             cardiovascular or pulmonary disease requiring pharmacologic intervention other than\n             anti-hypertensive medications, statins, and/or prophylactic aspirin (or similar\n             anticoagulant).\n\n          7. Red blood cell disorder, including (but not limited to): thalassemia major or minor,\n             sickle cell anemia.\n\n          8. Diabetes Mellitus treated with insulin or hypoglycemic agents\n\n          9. History of asthma requiring hospital admission within the preceding 12 months\n\n         10. History of alcohol abuse or illicit drug use which could interfere with a patient's\n             compliance with the protocol requirements, or with the safety or efficacy assessments\n             in this study\n\n         11. Patients requiring treatment, during this study, with any of the medications on the\n             restricted medications list (provided in the investigator site file), are not\n             eligible for this study due to considerations of possible drug interactions with the\n             study drug regimen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859962", 
            "org_study_id": "PPI-668-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 1, and Faldaprevir"
                ], 
                "intervention_name": "PPI-668", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 1, and Faldaprevir"
                ], 
                "intervention_name": "BI 207127 Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin", 
                "intervention_name": "BI 207127 Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 1, and Faldaprevir"
                ], 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin", 
                    "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin"
                ], 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin", 
                "intervention_name": "BI 207127 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Liver diseases", 
            "Virus diseases", 
            "Ribavirin", 
            "protease inhibitor", 
            "NS5B polymerase inhibitor", 
            "NS5A inhibitor"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94115"
                }, 
                "name": "Quest Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a)", 
        "overall_official": {
            "affiliation": "Presidio Pharmaceuticals, Inc.", 
            "last_name": "Nathaniel Brown, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the proportion of patients achieving sustained viral response (SVR)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after the end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859962"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with \"virologic relapse\" post-treatment, defined as confirmed and quantifiable (>LLOQ) serum HCV RNA in a patient who achieved non-detectable serum HCV RNA by the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks post-treatment"
            }, 
            {
                "description": "\"Confirmed viral breakthrough\" is defined as a > 1 log increase in HCV RNA from post-Baseline nadir value or confirmed increase in HCV RNA \u2265LLOQ if HCV RNA previously declined to <LLOQ (detected or not detected), during the 12-week study treatment period", 
                "measure": "Proportion of patients with confirmed viral breakthrough during study treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks of study treatment"
            }, 
            {
                "measure": "Proportions of study participants who receive at least one dose of study drug and who prematurely discontinue study treatment, and proportions prematurely discontinuing treatment for clinical adverse events or laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks of study treatment"
            }, 
            {
                "measure": "Proportions of study participants experiencing treatment-emergent adverse events (serious and non-serious) considered to be possibly or probably attributable to study treatment, overall and by body system", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks of study treatment"
            }
        ], 
        "source": "Presidio Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Presidio Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}